期刊文献+

强直性脊柱炎炎性骨破坏和病理性骨化的信号转导机制 被引量:9

The mechanism of signal transduction of inflammatory cytokines and pathological bone formation in ankylosing spondylitis
下载PDF
导出
摘要 炎性骨破坏和病理性骨化是强直性脊柱炎的特征性病理表现,有多种细胞因子和信号通路参与其中。目前,肿瘤坏死因子а、白细胞介素是最广为人知的参与炎性破坏的细胞因子,与此同时,伴随着越来越多新的生物学标志物的出现,Wnt/β-catenin信号通路、BMP/TGF-β信号通路等在AS骨化中的作用也日益受到重视。细胞因子介导的炎症与病理性骨化信号通路之间关系的研究,可能从分子水平上揭示强直性脊柱炎从炎症到骨化过程的机制,并为TNF抑制剂的长期临床应用提供依据。 The pathological features of ankylosing spondylitis (AS) include inflammatory bone destruction and ectopic bone formation. Variety of cytokines and signaling pathways are involved in these two processes. At present, tumor necrosis factor-a and interleukins are most well-known inflammatory cytokines which lead to bone damage. Meanwhile, appearing of many new biomarkers, such as Wnt/β-catenin signaling pathway and BMP/TGF-β signaling pathway, are attracting more and more attention. The study of the relationship between cytokines and signal pathways may reveal the mechanism of inflammation and pathological ossification in AS, which provides the evidence for the long-term use of anti-TNF drugs.
出处 《中国骨质疏松杂志》 CAS CSCD 北大核心 2015年第9期1132-1137,共6页 Chinese Journal of Osteoporosis
基金 广东省科技计划项目(2013B021800155)
关键词 强直性脊柱炎 TNF-A 白细胞介素 Wnt/β-catenin信号通路 BMP/TGF-β信号通路 生物学标志物 ankylosing spondylitis TNF-a Interleukins Wnt/β-catenin signaling pathway BMP/TGF-β signaling pathway Biomarkers
  • 相关文献

参考文献5

二级参考文献189

  • 1[1]Beutler BA.The role of tumor necrosis factor in health anddisease.J Rheumatol,1999,57(1):16-21.
  • 2[2]Braun J,Bollow M,Neure L,et al.Use of immunohistologic and insitu hybridization techniques in the examination of sacroiliac jointbiopsy specimens from patients with ankylosing spondylitis.Arthritis Rheum,1995,38(4): 499-505.
  • 3[3]Brandt J,Haibel H,Sieper J,et al.Infliximab treatment of severeankylosing spondylitis:one-year follow-up.Arthritis Rheum,2002,44(12):2936-2945.
  • 4[4]Brandt J,Haibel H,Cornely D,et al.Successful treatment of activeankylosing spondylitis with the anti-tumor necrosis factor-αmonoclonal antibody infliximab.Arthritis Rheu,2000,43(6):1346-1352.
  • 5[5]Braun J,Brandt J,Listin J,et al.Treatment of active ankylosingspondylitis with infliximab: a randomized controlled multicentertrial.Lancet,2002,359(9313): 1187-1193.
  • 6[8]Gu J,Rihl M,Marker-Hermann E,et al.Clues to pathogenesis ofSpondyloarthropathy derived from synovial-fluid-mononuclearcell gene expression profiles.J Rheumatol,2002,29(10):2159-64.
  • 7[9]Seta N,Granfors K,Sahly H,et al.Expression of host defensescavenger receptors in spondyloarthropathy.Arthritis Rheum,2001,44(4): 931-939
  • 8[10]Elsen M,Spellman P,Brown P,et al.Cluster analysis and display ofgenome-wide expression patterns.Proc Natl Acad Sci USA,1998,95:14863-14868.
  • 9[11]Cunnane G,Fitzgerald O,Beeton C,et al.Early joint erosions andserum levels of matrix metalloproteinase 1,matrix metalloproteinase3,and tissue inhibitor of metalloproteinases 1 in rheumatoidarthritis.Arthritis Rheum,2002,44(10):2263-2274.
  • 10[12]Hotary KB,Yana I,Sabeh F,et al.Matrix metalloproteinases (MMPs)regulate fibrin-invasive activity via MT1-MMP-dependent andindependent processes.J Exp Med,2002,195:295-308.

共引文献95

同被引文献52

引证文献9

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部